Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and confirms FY guidance range Fagron, the leading global player in pharmaceutical compounding, today publishes its ...

COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade to the financial guidance for the full year 2026, reflecting stronger-than-expected performance in its ...

“Completing Phase 1 and the decision by Neurosterix to progress NTX-253 into Phase 2 studies in schizophrenia patients is a significant achievement,” said Tim Dyer, CEO of Addex. “The well-designed ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous ...

Bio Usawa Biotechnology today announced the launch of Bio Usawa Biotech Botswana (Pty) Ltd, marking an important milestone in the company’s mission to build a self-sustaining biotechnology ecosystem ...

First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease ...

Neo-Essentialism is not meant to replace existing schools of thought. Minimally invasive dentistry, biomimetic dentistry, adhesive dentistry, preventive care, and regenerative approaches have all ...

SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic ...

What: Clover Health’s Third Quarter 2026 Earnings Conference Call When: Wednesday, November 4, 2026, at 5:00 p.m. Eastern Time A live and archived webcast of the conference call will also be ...

Rockville, Md., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Embark Behavioral Health announced today that its intensive outpatient clinic in Rockville will relocate to a larger space in Germantown, with the ...

Preclinical studies conducted at Augusta University using the Townes sickle cell disease mouse model showed that HPPD was orally active and well tolerated, increased fetal hemoglobin, and reduced ...

Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes Petrelintide achieved up to 9.2% mean body ...